How General and Inflammatory Status Impacts on the Prognosis of Patients Affected by Lung Cancer: State of the Art

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Jul 27

PMID 39062127

Authors

Antonio Mazzella

Riccardo Orlandi

Sebastiano Maiorca

Clarissa Uslenghi

Matteo Chiari

Luca Bertolaccini

Monica Casiraghi

Giorgio Lo Iacono

Lara Girelli

Lorenzo Spaggiari

Affiliations

Soon will be listed here.

Abstract

Pulmonary cancer is often associated with systemic inflammation and poor nutritional status and these two aspects are strongly correlated and related to the scarce infiltration of a tumor by immune cells. We reviewed all English literature reviews from 2000 to 2024 from PubMed, Scopus and Google Scholar, including original articles, review articles, and metanalyses. We excluded non-English language articles and case reports/case series. Generally speaking, nutritional and inflammatory status largely affect medium and long-term prognosis in lung cancer patients. A correct stratification of patients could improve their preoperative general functional nutritional and inflammatory status, minimizing, therefore, possible treatment complications and improving long-term prognosis.

References

Mazzella A, Mohamed S, Maisonneuve P, Borri A, Casiraghi M, Bertolaccini L . ARDS after Pneumonectomy: How to Prevent It? Development of a Nomogram to Predict the Risk of ARDS after Pneumonectomy for Lung Cancer. Cancers (Basel). 2022; 14(24). PMC: 9775532. DOI: 10.3390/cancers14246048. View

Godschalk R, Feldker D, Borm P, Wouters E, van Schooten F . Body mass index modulates aromatic DNA adduct levels and their persistence in smokers. Cancer Epidemiol Biomarkers Prev. 2002; 11(8):790-3. View

Sorensen J . Lung Cancer Cachexia: Can Molecular Understanding Guide Clinical Management?. Integr Cancer Ther. 2018; 17(3):1000-1008. PMC: 6142092. DOI: 10.1177/1534735418781743. View

Leuzzi G, Galeone C, Gisabella M, Duranti L, Taverna F, Suatoni P . Baseline C-reactive protein level predicts survival of early-stage lung cancer: evidence from a systematic review and meta-analysis. Tumori. 2016; 102(5):441-449. DOI: 10.5301/tj.5000522. View

Calder P, Ahluwalia N, Albers R, Bosco N, Bourdet-Sicard R, Haller D . A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies. Br J Nutr. 2013; 109 Suppl 1:S1-34. DOI: 10.1017/S0007114512005119. View

Alifano M, Mansuet-Lupo A, Lococo F, Roche N, Bobbio A, Canny E . Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. PLoS One. 2014; 9(9):e106914. PMC: 4169516. DOI: 10.1371/journal.pone.0106914. View

Mytelka D, Li L, Benoit K . Post-diagnosis weight loss as a prognostic factor in non-small cell lung cancer. J Cachexia Sarcopenia Muscle. 2017; 9(1):86-92. PMC: 5803614. DOI: 10.1002/jcsm.12253. View

Gonzalez M, Pastore C, Orlandi S, Heymsfield S . Obesity paradox in cancer: new insights provided by body composition. Am J Clin Nutr. 2014; 99(5):999-1005. DOI: 10.3945/ajcn.113.071399. View

Shachar S, Williams G . The Obesity Paradox in Cancer-Moving Beyond BMI. Cancer Epidemiol Biomarkers Prev. 2017; 26(1):13-16. PMC: 5830139. DOI: 10.1158/1055-9965.EPI-16-0439. View

10.

Liang B, Wang S, Ye Y, Yang X, Wang Y, Qu J . Impact of postoperative omega-3 fatty acid-supplemented parenteral nutrition on clinical outcomes and immunomodulations in colorectal cancer patients. World J Gastroenterol. 2008; 14(15):2434-9. PMC: 2705104. DOI: 10.3748/wjg.14.2434. View

11.

Weiss G, Meyer F, Matthies B, Pross M, Koenig W, Lippert H . Immunomodulation by perioperative administration of n-3 fatty acids. Br J Nutr. 2002; 87 Suppl 1:S89-94. DOI: 10.1079/bjn2001461. View

12.

Wang L, Si H, Wang J, Feng L, Zhai W, Dong S . Blood cell parameters as prognostic predictors of disease development for patients with advanced non-small cell lung cancer. Oncol Lett. 2020; 20(2):1101-1110. PMC: 7377095. DOI: 10.3892/ol.2020.11655. View

13.

Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S . Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017; 84:212-218. DOI: 10.1016/j.ejca.2017.07.027. View

14.

Wang Y, Fang K, Hsu C, Chang G, Lai C, Lee Y . Retrospective study on the potential of albumin/globulin ratio as a prognostic biomarker for oral cavity cancer patients. Eur Arch Otorhinolaryngol. 2020; 278(1):227-238. DOI: 10.1007/s00405-020-06145-x. View

15.

Bhaskaran K, Douglas I, Forbes H, Dos-Santos-Silva I, Leon D, Smeeth L . Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014; 384(9945):755-65. PMC: 4151483. DOI: 10.1016/S0140-6736(14)60892-8. View

16.

Cruz-Bermudez A, Vicente-Blanco R, Laza-Briviesca R, Garcia-Grande A, Laine-Menendez S, Gutierrez L . PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy. Sci Rep. 2017; 7(1):16661. PMC: 5709355. DOI: 10.1038/s41598-017-17009-6. View

17.

Zhang Y, Cui G, Xiu Y, Zhao M . The Effect of Nutritional Support Based on the Dietary Anti-Inflammatory Index on Cancer-Related Fatigue in Lung Cancer Patients Undergoing Chemotherapy. Cancer Nurs. 2023; 46(5):394-404. DOI: 10.1097/NCC.0000000000001124. View

18.

Choi J, Villarreal J, Lasala J, Gottumukkala V, Mehran R, Rice D . Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study. Cancer Med. 2015; 4(6):825-33. PMC: 4472205. DOI: 10.1002/cam4.428. View

19.

Suzuki Y, Okamoto T, Fujishita T, Katsura M, Akamine T, Takamori S . Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer. Lung Cancer. 2016; 101:92-97. DOI: 10.1016/j.lungcan.2016.08.007. View

20.

Forget P, Machiels J, Coulie P, Berliere M, Poncelet A, Tombal B . Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol. 2013; 20 Suppl 3:S650-60. DOI: 10.1245/s10434-013-3136-x. View